GlobeNewswire by notified

MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States

Share


NEWS RELEASE – REGULATED INFORMATION
15 November 2021, 11:00 p.m. CET

MDxHealthShareholder Transparency Declarations

IRVINE, CA, and HERSTAL, BELGIUM – 15 November 2021 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notifications of significant shareholdings.

MDxHealth was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold of 10% of the outstanding shares and voting rights of MDxHealth on 4 November 2021. Notably, it follows from the notification that an aggregate of 21,783,330 shares of MDxHealth, representing 13.97% of the 155,969,226 outstanding shares and voting rights of MDxHealth (taking into account the capital increase that was announced on 4 November 2021 and that was completed on 8 November 2021), is held through the following entities: 21 April Fund LP (5,266,830 shares), 21 April Fund LTD (13,599,830 shares), Hill Family Alternative Investments LLC (2,500,000 shares), and White Clover SA (416,670 shares) (the "Funds"). The notification also stated that the voting rights attached to the shares are exercised on behalf of the Funds by the investment adviser Bleichroeder LP, a Delaware limited partnership, at its discretion, in the absence of specific instructions, that Bleichroeder Holdings LLC, a Delaware limited liability company, is the general partner of Bleichroeder LP, that, as the general partner, Bleichroeder Holdings LLC holds control over voting rights of Bleichroeder LP, and that Bleichroeder Holdings LLC is not a controlled entity.

MDxHealth was notified that the number of shares with respect to which Soleus Capital Management, L.P. can exercise voting rights actively crossed below the threshold of 5% of the outstanding shares and voting rights of MDxHealth on 5 November 2021. Notably, it follows from the notification that 5,829,261 shares of MDxHealth, representing 4.92% of 118,469,226 outstanding shares and voting rights of MDxHealth (which, taking into account the capital increase that was announced on 4 November 2021 and that was completed on 8 November 2021, represents 3.97% of 155,969,226 outstanding shares and voting rights of MDxHealth), are held through Soleus Capital Master Fund, L.P. The notification also stated that the voting rights attached to the shares are exercised by the investment advisor Soleus Capital Management, L.P., a Delaware limited partnership, at its discretion, in the absence of specific instructions, that Soleus Capital Master Fund, L.P. is a limited partnership formed in the Cayman Islands, that Soleus Capital Management, L.P. is controlled by a sole general partner, Soleus GP, LLC, a Delaware limited liability company, and that Soleus GP, LLC is controlled by its sole member, Mr. Guy Levy.

For further information, reference is made to the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

About MDxHealth®
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:
MDxHealth
info@mdxhealth.com

Important information

The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

TGS Share Repurchase2.12.2021 10:57:49 CET | Press release

Oslo, Norway (02 December 2021) – On period from 25 November 2021 to 01 December 2021, TGS ASA (TGS) purchased 67,328 own shares on the Oslo Stock Exchange at an average price of NOK 85.1890 per share. Following the purchase TGS owns 1,226,303 shares, representing 1.044% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)25-Nov-2110,87888.9977968,11726-Nov-2120,00084.97931,699,58629-Nov-212,00084.2400168,48030-Nov-2120,00084.16361,683,2721-Dec-2114,45084.16241,216,147Previously disclosed buy-backs under the program (accumulated)1,143,975105.5774120,777,940Accumulated under the buy-back program1,211,303104.4442126,513,541The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,226,303 own shares, corresponding to

AB Linas Agro Group investors calendar for the 20222.12.2021 10:41:10 CET | Press release

A list of key information disclosure dates in 2022: February 28, 2022Interim half-year unaudited report for FY 2021/2022.March 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2021/2022.May 31, 2022Interim unaudited report for 9 months of FY 2021/2022.June 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2021/2022.August 31, 2022Interim unaudited report for 12 months of FY 2021/2022.September 2, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2021/2022.Week 40 (Oct 3-7, 2022)Notice on Annual General Meeting of shareholders.Week 43 (Oct 24-28, 2022) Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2021/2022.November 30, 2022Interim unaudited report for 3 months of 2022/2023 financial year.December 1, 2022Investor Conference Webinar to introduce unaudited financial an

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS2.12.2021 10:10:00 CET | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-12-02Loan194Coupon1.00 %ISIN-codeSE0012142206Maturity2024-09-18 Tendered volume, SEK mln400 +/- 200 Volume offered, SEK mln1,600 Volume bought, SEK mln600 Number of bids5 Number of accepted bids3 Average yield0.230 %Lowest accepted yield0.226 %Highest yield0.234 %% accepted at lowest yield 50.00 Auction date2021-12-02Loan1594Coupon2.00 %ISIN-codeSE0011062892Maturity2028-09-01 Tendered volume, SEK mln1,300 +/- 650 Volume offered, SEK mln2,600 Volume bought, SEK mln50 Number of bids5 Number of accepted bids1 Average yield0.857 %Lowest accepted yield0.857 %Highest yield0.857 %% accepted at lowest yield 100.00 Auction date2021-12-02Loan146Coupon0.50 %ISIN-codeSE0013381571Maturity2025-06-11 Tendered volume, SEK mln600 +/- 300 Volume offered, SEK mln1,700 Volume bought, SEK mln900 Number of bids3 Number of accepted bids2 Average yield0.395 %Lowest accepted yield0.395 %Highest yield0.395 %% accepted at lowest yield 81.82

Incap Corporation: Incap’s schedule for financial reporting in the year 20222.12.2021 08:30:00 CET | Press release

Incap Corporation: Incap’s schedule for financial reporting in the year 2022 Incap Corporation will publish the following financial reports in 2022: financial statements release for 2021 on Thursday, 24 February 2022 annual report for 2021 during week 13/2022 (week commencing on 28 March 2022) business review for January-March 2022 on Wednesday, 27 April 2022 half-year report for January-June 2022 on Thursday, 28 July 2022 business review for January-September 2022 on Thursday, 27 October 2022. The annual report includes the report of the Board of the Directors, the financial statements of the Group and the parent company as well as the auditor’s report for the financial period 1 January–31 December 2021. At the same time, the company will also publish the corporate responsibility report, the report on Corporate Governance as well as the report on remuneration. Incap’s Annual General Meeting is scheduled to be held on Friday, 29 April 2022 in Helsinki. A shareholder has the right to ha

Strategic Business Update - Acquisition of Precise-ITC and completion of major milestones for China Product Partnership2.12.2021 08:00:00 CET | Press release

LONDON and TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alphawave IP (LN:AWE), a global leader in high-speed connectivity for the world’s technology infrastructure, is pleased to announce the acquisition of Precise-ITC and the completion of significant milestones for the China Product Partnership (“CPP”). Key highlights Alphawave IP has agreed to acquire Precise-ITC, Inc., an emerging leader in the Ethernet and Optical Transport Network (OTN) communications connectivity IP space. Alphawave IP has also completed all CPP implementation milestones and CPP, now incorporated as WiseWave Technology Co., Ltd (“WiseWave”), has been funded and will receive its first IP delivery from Alphawave IP in December 2021, as planned. WiseWave was founded as a Chinese semiconductor device company focused on the mainland Chinese market. In addition, Alphawave IP has completed the consolidation of its VeriSilicon reseller relationship with WiseWave to provide one interface to customers in China, in line with

Terranet Capital Markets Day on the 6th of December is around the corner2.12.2021 08:00:00 CET | Press release

On the 6th of December Terranet welcomes you to an exclusive day where you will be exposed to some of the avant garde brains in the Terranet ecosystem and the global automotive industry. At this event Terranet will reveal the latest progress and milestone achievements and showcase some insights behind the industry-collaborations. Please ensure you reserve your seat for the event in Stockholm here, only limited seats availiable: https://bit.ly/3mflryl Each presentation will be broadcasted and distributed live digitally. Sign up here: https://bit.ly/3B308UP Please find the updated schedule below: The schedule of the day (CET): 10:10 - 10.15 Ronja Koepke, Moderator 10:15 - 10.25 Par-Olof Johannesson, CEO Terranet 10:25 - 10:30 Ronja Koepke, Moderator 10:30 - 10.45 Jan Glevén, Head of Insight Mangold Fondkommission. 10:45 - 10.50 Ronja Koepke, Moderator 10:50 - 11:05 Panel discussion Jan Glevén, Head of Insight Mangold Fondkommission & Hampus Engellau, Handelsbanken Capital Markets 11.05 -

Systemairs rapport för det andra kvartalet presenteras den 9 december2.12.2021 08:00:00 CET | Pressemelding

Pressmeddelande 2 december 2021 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q2 för räkenskapsåret 2021/22 kommer att offentliggöras kl. 08:00 CET den 9 december 2021. En telefonkonferens arrangeras kl. 09:00 CET den 9 december 2021. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 0200-883 685 alt. internationellt +46 8 566 426 51 och uppge kod 50215855# minuter före start. Presentationen publiceras på group.systemair.com För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, www.systemair.com Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 54 länder i Europa, Nordamerika, Sydamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 8,5 miljarder kronor räkenskapsåret 2020/21 och har cirka 6 400 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat po